Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound-Guided fluid removal could save kidneys in ICU patients

NCT ID NCT07346118

Disease control Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a special ultrasound technique (mVExUS) to guide how much fluid is removed during dialysis can improve outcomes for critically ill patients with acute kidney injury. 126 adults in the ICU will be randomly assigned to either standard care or the ultrasound-guided approach. The main goal is to see if the ultrasound method leads to a better fluid balance over 72 hours and fewer complications like low blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ultrasound-guided fluid management (mVExUS protocol)
What this could lead to
If it works, this could lead to a more precise way to manage fluid levels in critically ill kidney patients, potentially reducing complications and improving survival.
What could go wrong
This is a small, early-stage trial (126 participants) testing a new ultrasound method. The approach may not improve outcomes over standard care, and results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 126 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥ 18 years of age) * Admitted to ICU * Acute kidney injury by KDIGO criteria * Initiated CRRT by at least one of the following indications for RRT initiation: * Serum potassium ≥ 6.0 mmol/L, or * pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L, or * Evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload, or * Persistent severe AKI (sCr remains \> 50% the value recorded at randomization) for \> 72 hours from randomization * Participants giving informed consent Exclusion Criteria: * Refuse to participate * Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy * Kidney transplant recipient * Receive RRT before ICU admission within 90 days * Structural kidney diseases which will interfere with intrarenal doppler ultrasound e.g. renal artery stenosis, autosomal dominant polycystic kidney disease * Patients with previously known conditions that interfere with portal doppler assessment, namely liver cirrhosis, severe tricuspid regurgitation with structural heart disease or massive ascites. * Underlying disease process with a life expectancy less than 90 days * Pregnancy * Severe cardiac rhythm disturbances (tachyarrhythmia, supraventricular tachycardia) * Intra-cardiac shunts; Ventricle septal defect, patent foramen ovale, atrial septal defect * Aortic aneurysm * Intra-abdominal hypertension (intraabdominal pressure ≥20 mmHg) * Expected life expectancy \<48 hours * Receiving extracorporeal membrane oxygenation (ECMO)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute circulatory failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury Shock VEXAS syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute circulatory failure AKI - acute kidney injury Biomarkers / blood Continuous renal replacement therapy (CRRT) Fluid balance Passive leg raising VEXUS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.